Journal
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/alr.23185
Keywords
biologics; biosimilars; chronic rhinosinusitis; cost; Medicare; nasal polyps; omalizumab; price; utilization
Categories
Ask authors/readers for more resources
Between January 2005 and January 2023, the average selling price of omalizumab increased by nearly 60%. Between 2016 and 2021, Medicare Part B and D spending on omalizumab totaled over $3.7 billion. Between 2016 and 2021, Medicare Part B and D utilization of omalizumab increased by approximately 30%.
Key PointsBetween January 2005 and January 2023, the average selling price of omalizumab increased by nearly 60%.Between 2016 and 2021, Medicare Part B and D spending on omalizumab totaled over $3.7 billion.Between 2016 and 2021, Medicare Part B and D utilization of omalizumab increased by approximately 30%.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
